Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid added to standard therapy for high-risk localized breast cancer
ACTRN12606000293561Phase 3Active, not recruiting
- Sponsor
- University of Sheffield
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in breast cancer (2 arms), sponsored by University of Sheffield. Primary endpoint: Disease-free survival. Started Sep 2003; status: active, not recruiting.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000293561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000293561.